Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Not yet showing here:
Cambridge, UK, 9 August 2021 - Sareum Holdings plc (AIM: SAR), the specialist drug development company, announces that it has raised £1,000,000, before expenses, through a subscription by a high net worth individual (the "Subscriber") for 12,121,212 new ordinary shares of 0.025p each in the capital of the Company ("Ordinary Shares") (the "Subscription Shares") at a price of 8.25p per share (the "Subscription Price") (the "Subscription").
Under the terms of the Subscription, the new Subscriber will also be issued one and a quarter five-year warrants, exercisable at the Subscription Price, for every Subscription Share issued (the "Subscription Warrants"), which can only be exercised following the Company's closing middle market share price being above 10.25p per Ordinary Share for five consecutive days. The Subscription Price represents a discount of approximately 6.8 per cent. to the closing middle market price for Sareum shares on 6 August 2021.
The net proceeds from the Subscription will be used to progress the Company's SDC-1801 and SDC-1802 TYK2/JAK1 inhibitor drug development programmes as well as for working capital purposes. As noted in the Company's Trading Update of 25 May 2021, the Company is targeting the filing of a Clinical Trials Approval for SDC-1801 in Q4 2021, subject to successful progress and no further delays with the final preclinical studies. Clinical trial plans, including priority autoimmune indications and potential Covid-19 application, will also be developed in parallel, subject to additional funding being raised.
Application will be made for the 12,121,212 Subscription Shares, which will rank pari passu with the Company's existing Ordinary Shares, to be admitted to trading on the AIM market of the London Stock Exchange ("AIM") ("Admission"). It is anticipated that Admission will become effective at 8.00 am on 17 August 2021. The Subscription is subject to normal conditions including, inter alia, Admission.
Total Voting Rights
For the purpose of the Disclosure Guidance and Transparency Rules, following the above issue of equity, the issued share capital of the Company will comprise 3,365,701,148 Ordinary Shares. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure Guidance and Transparency Rules.
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "This new subscription is Sareum's fourth since 1 June this year, reflecting the strong and continuing interest in our proprietary TYK2/JAK1 development programmes in autoimmune diseases, including the immune overreaction to Covid-19, and cancer. With the funds raised during this period now totalling over £4.5 million, our financial position has been significantly strengthened and we are looking forward to completing the preclinical studies with SDC-1801 and adva
"Prior to the pandemic last year, the COVID 19 of many countries in warmer climates was Malaria. Therefore, it is highly significant that pharma services group Open Orphan (ORPH) has revealed that its subsidiary, hVIVO, has developed a Controlled Human Malaria Infection challenge model. Open Orphan said that this development strengthens and further diversifies the company's world leading portfolio of viral challenge study models. The Malaria challenge model will assist in the advancement of antimalarial drug and vaccine candidates from November 2021. Results from CHMI modelling of drug and vaccine efficacy have previously shown good translation into the field."
See it's business as usual here still..
I asked the question the other week:
Once further details surrounding the Poolbeg shares have been released we will be able to confirm whether they can be supported on the platform once actually received. If they can be supported, Poolbeg will be automatically listed. You will receive an email from our corporate actions team regarding this.
?We will provide further information once known, however, please do buzz us if you have any questions! ??
Let me know if you have any questions!
Invite received already
Not sure I agree with that, James parsons is one of the biggest ****s known to man. Not sure CF has the same patter, certain doesn't quote £xxx won't cut it!
F-cking mental, I was thinking this earlier when I saw it. So your free to walk around, thinking you feel fine, during incubation period, honest to god.
And to quote:
"Researchers estimate that people who get infected with the coronavirus can spread it to others 2 to 3 days before symptoms start and are most contagious 1 to 2 days before they feel sick."
Look at the dates..
Seems sites screwed again.
As already stated April
30-Apr-21 10:57:37 450.52 1,000 Unknown* 4,505 O
30-Apr-21 10:49:00 450.51773 1,410 Unknown* 6,352 O
30-Apr-21 10:57:33 450.52 2,000 Unknown* 9,010 O
30-Apr-21 10:48:47 450.5127 1,473 Unknown* 6,636 O
30-Apr-21 10:57:18 450.52 1,000 Unknown* 4,505 O
30-Apr-21 10:57:17 450.52 1,000 Unknown* 4,5
Same here novice,
Try this
https://www.ft.com/content/6cec5334-265b-4de7-b176-9d854cce4d86
Lol, was going to say bit early to be pi55ed on half a shandy
Agree Harchris, ...been like that here for a long time..
They have registered a trademark, doesn't mean anything is going anywhere.
Like orph, they only release news on contracts over a certain value.
Just waiting on the Monday rns on what sandwiches they are having for the week...
https://mobile.twitter.com/Blad3sharp/status/1416099321083310087
https://mobile.twitter.com/larry64450205/status/1322971456494571520
Lmfao, price goes up, speculation twats arrive, nothing changes here.
Must be a take over....
That crap was posted on another board yesterday